Detection of minimal residual disease (MRD) is a powerful prognostic tool in many hematological malignancies including ALL. 1 Several groups of markers are widely used to monitor the concentration of a malignant clone including the detection of 'clonal B-cell (BCR) or T-cell (TCR) gene receptor rearrangements 2 in ALL. Identification of a clonal rearrangement specific for the malignant clone, which usually constitutes from 20 to 90% in the initial bone marrow sample is a relatively straightforward task.
2 Tracking this rearrangement after therapy is more tricky as the concentration of malignant cells in the sample can be very low. Recent progress in MRD detection based on quantitative real-time PCR (qPCR) 3 and highthroughput sequencing (HTS) [4] [5] [6] allows to detect malignant clones present at a concentration of one per 10 5 and even per 10 6 cells. Although MRD detection is claimed to be able to accurately predict the outcomes of leukemia therapy in different clinical settings, the value of this information is sometimes corrupted by false-positive and false-negative results of MRD measurement. 7 One of the potential causes of false-positive results is discussed below.
Ig and TCR genes used for MRD monitoring are the most variable genes in the human organism. They are formed via the specific V(D)J recombination mechanism in each of the T or B-cell clones during maturation by joining one of each V, D and J genomic segments and inserting random nucleotides to the segment junctions. The principal theoretical diversity of TCRβ chain in humans is estimated at 10 14 different variants 8 and up to 10 18 for BCRs heavy chains. 9 As the probability of an independent recombination event in a normal cell leading to the same receptor sequence is very low, the detection of the same leukemic TCR or BCR rearrangement after therapy, at first sight, unambiguously indicates the presence of malignant cells. However, recent studies indicate that the generation probability of different TCR or BCR rearrangements can vary by several orders of magnitude. Moreover, some sequence variants could be found almost in each individual (so called public clonotypes [10] [11] [12] ). Thus estimation of TCR and BCR rearrangement probabilities is essential for reliable MRD monitoring.
The generation probability of an immune receptor nucleotide sequence is a sum of probabilities of all possible combinations of events which lead to this sequence formation, including V, D, J gene segments selection, deletions of nucleotides from the edges of gene segments and insertion of random (N) nucleotides. 8, 9 Here, we analyzed 63 TCRβ rearrangements, including 56 previously published rearrangements of malignant clones and 7 clonal rearrangements that we identified for 10 patients with T-cell or B-cell acute lymphoblastic leukemia using Biomed 2 primers for amplification 2 and Sanger sequencing. Using the probabilistic generation model (described in detail in ref. 8 and in Supporting Information), and our in-house software we computed generation probabilities for each of the 63 malignant TCRβ rearrangements (Supplementary Table 1 ). To evaluate how probabilities of malignant TCRβ rearrangements correspond to those of healthy T-cell clones, we calculated the distribution of generation probabilities for 145 individual TCRβ repertoires from healthy donors (refs 13-15 and our unpublished data) obtained previously using our NGS (Illumina HiSeq, San Diego, CA, USA) based technology. 16 We calculated two different probability distributions: (1) for TCRs that are found only in one individual ('unique clones', 40 667 025 total), and (2) for TCRs that are present at least in two individuals ('shared clones', 2 524 069 total) ( Figure 1a ). In general, the distribution of malignant clones was close to that of unique clones. However, 9 out of 63 pathogenic rearrangements had high generation probabilities characteristic for shared clones (around 1х10 − 9 ). Further, we searched for the CDR3 nucleotide sequences of malignant TCRβ clones in the repertoires of the same 145 healthy individuals (Table 1A ) and found that 5 out of 63 rearrangements of malignant clones (CDR3 nucleotide sequences) are present in at least one healthy donor. For one rearrangement, we observed identical nucleotide CDR3 sequences in 20 out of 145 healthy individuals. Further analysis of healthy TCR clones with the CDR3s identical to those of malignant clones showed that some of them had a different V gene (Tables 1A, H0 in parentheses). However, even if this strict criterion (identical V gene) was applied, the 5 rearrangements of malignant clones were found in at least one healthy individual. As might be expected, TCR rearrangements of malignant clones found in healthy donors had high-generation probabilities (Figure 1a , solid red lines, Table 1A , generation probability).
Density
To evaluate if the number of found clones (5 out of 63) is close to expected, we performed Monte-Carlo simulation. From each of the 76 healthy TCR repertoires, which have more than 200 000 clonotypes we randomly chose 63 TCRβ clones and searched for them in the other 144 repertoires, and repeated the procedure seven times (7 × 76 simulations in total). The simulation showed that on average 6 of 63 randomly chosen clones were found in other individuals (median 6, 95% confidence interval: 2, 16). Thus the number of malignant clonotypes found in healthy donors is close to expected. qPCR method widely used for MRD detection does not have absolute specificity as CDR3 specific fluorescent probes can anneal to similar sequences. Thus, we also searched for healthy TCRβ clones with CDR3 sequence homologous to malignant clones CDR3s (Table 1B) . In total 18 out of 63 malignant clones had shared TCRβ rearrangements with the same V and J genes and no more than one nucleotide mismatch in the CDR3 sequence among healthy individuals. Distribution of generation probabilities for these 18 rearrangements corresponds to the distribution of shared healthy clonotypes, whereas the distribution for other malignant rearrangements corresponds to that of unique clones (Figure 1b) .
MRD monitoring is critical for the choice of the most efficient strategy for the post-remission therapy including hematopoietic stem cell transplantation. Although modern MRD monitoring methods based on qPCR or HTS have reasonably high sensitivity, they never account for the generation frequency of monitored immune gene rearrangements. Therefore, there is a probability that the TCR or BCR sequences identical to that characteristic for the malignant clone can be formed independently in healthy immune cells. In this case, MRD follow up data may become misleading, as the rearrangement detected after chemotherapy does not necessarily indicate the presence of tumor cells.
Here, we show that TCRβ rearrangements with relatively high generation probabilities are found in malignant cells. Moreover, some of these rearrangements (4 out of 9) are found in the TCR repertoires of normal individuals. The number of healthy individuals having the same CDR3 sequence as malignant clones is also quite small ranging from 1 to 5 out of 145 in most cases. Thus, at the first sight, the chance of making a wrong conclusion in course of MRD monitoring is relatively low. However, Table 1A . Letter to the Editor it should be mentioned that the probability of an independent identical rearrangement in the same organism is substantially higher than in other individuals. Besides that only direct sequencing based methods are able to distinguish an identical CDR3 sequence from a very similar one (with a single mismatch). When using qPCR-based methods, an independently formed rearrangement with a single mismatch can result in a false-positive signal as a fluorescent probe complementary to the CDR3 region or CDR3 specific primer is used. In this study, 18 out of 63 analyzed malignant TCRβ rearrangements could generate false-positive signals.
Here, we focused on TCRβ rearrangements that are used to monitor MRD for both B and T ALL. For Ig heavy chains (IGH) that are also often used for MRD monitoring the risk to obtain false-positive result is essentially lower, as rearranged IGH genes contain more added random nucleotides at the junctions and in addition hypermutations occur in genomically encoded regions. At the same time other immune receptor loci that are also used for MRD monitoring (Ig light chains IGL, IGK and TCR gamma) include only two genomic segments V and J and fewer added nucleotides at the junction, which increases the risk of false-positive results. Thus, additional studies are needed to evaluate the risk of false-positive MRD monitoring results with other IG markers.
Thus, our data indicate that immune gene rearrangements should be evaluated with respect to the probability of their independent assembly in course of MRD monitoring. This evaluation can be performed using two approaches: (1) calculation of a rearrangement probability using mathematical modeling or (2) direct search for the rearranged sequence in a reasonable dataset of IG or TCR repertoires of healthy donors. As a result of such analysis, candidate markers can be ranked for their potential reliability for the MRD monitoring. In cases with clonotypes characterized by high-generation frequency, MRD analysis should be supported by other leukemia-specific genetic markers.
